Adamas Pharmaceuticals reported 3.5M in Interest Expense on Debt for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Adamas Pharmaceuticals ADMS:US 3.5M 28K
Aerie Pharmaceuticals AERI:US $ 7.36M 0.24M
Biocryst Pharmaceuticals BCRX:US $ 14.12M 0.62M
Flexion Therapeutics FLXN:US $ 6.29M 1.11M
Gw Pharmaceuticals GWPH:US $ 0.29M 0.02M
Marinus Pharmaceuticals MRNS:US 678K 327K
Neurocrine Biosciences NBIX:US $ 6.6M 0.4M
Novartis NOVN:VX 202M 1000K
Omeros OMER:US $ 4.91M 1000
Revance Therapeutics RVNC:US $ 1.57M 2K
Teva Pharmaceutical TEVA:IT 232M 8M
Zogenix ZGNX:US $ 3.85M 0.06M